Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use

Dupilumab is a humanized monoclonal antibody approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, atopic dermatitis, eosinophilic esophagitis, and prurigo nodularis. The most common adverse reactions from dupilumab use are temporary injection site reactions and...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacheco, Curtis S, White, Kevin M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174336/
https://www.ncbi.nlm.nih.gov/pubmed/37182063
http://dx.doi.org/10.7759/cureus.37441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174336/
https://www.ncbi.nlm.nih.gov/pubmed/37182063
http://dx.doi.org/10.7759/cureus.37441

Ejemplares similares